引導式測驗 · 中等 等級
人工智慧在肝臟疾病和肝病學測驗的應用
測試肝臟病理學評分、超音波研究、移植風險模型、FDA 資格範圍和專業審查。
問題 1 的 8
FDA 在什麼情況下將 AIM-NASH 授予藥物開發工具資格?
預覽每個問題8 問題
當您參加測驗時,就會出現答案和解釋。
- FDA 在什麼情況下將 AIM-NASH 授予藥物開發工具資格?
- Diagnosing all liver diseases from a blood test
- Setting transplant priority in every country
- Scoring liver-biopsy features in MASH clinical trials
- Replacing liver biopsy with ultrasound
- 誰對 AIM-NASH 活檢評分做出最終解釋?
- The AI tool alone
- The pathologist after reviewing the whole slide and AI output
- The trial sponsor
- A transplant coordinator
- 為什麼超音波和活檢人工智慧結果應該被視為不同的任務?
- Every imaging method measures the same tissue directly
- A biopsy model automatically validates ultrasound
- Ultrasound tools never use AI
- They use different inputs and reference standards
- GEMA-AI 研究估計了什麼?
- A waitlist outcome estimate for transplant candidates using clinical variables
- A histology grade for steatosis in biopsy images
- A radiology score for liver ultrasound texture
- A classification of cancer-signal origin in blood
- 研究模型是否會自動成為移植分配規則?
- Yes, once it has an external test set
- Yes, when it uses the same lab variables
- No; allocation requires policy and multidisciplinary review
- No, because prediction models cannot use lab results
- Which liver-biopsy features does AIM-NASH score?
- Kidney filtration, blood pressure and sodium only
- Steatosis, inflammation and fibrosis
- Thyroid shape, margin and echogenicity
- Tumor stage and medication response
- What should a liver imaging team check before using an AI fibrosis score?
- That the model was trained on any organ image
- Only whether the report is short
- Whether a transplant list is available
- That the model was validated for the relevant imaging task and patient group
- What remains central in transplant allocation decisions?
- Policy, equity, organ availability and transplant-team review
- The highest model score alone
- An ultrasound image without other information
- A model vendor’s ranking